|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Rosuvastatin#Adult Indications and Dosage]] |
| {{Rosuvastatin}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
|
| |
|
| ==Indications and Usage==
| | [[Category: Cardiovascular Drugs]] |
| | | [[Category: Drug]] |
| ===Hyperlipidemia and Mixed Dyslipidemia===
| |
| | |
| CRESTOR is indicated as adjunctive therapy to diet to reduce elevated Total-C, LDL-C, ApoB, nonHDL‑C, and [[triglyceride]]s and to increase HDL‑C in adult patients with primary [[hyperlipidemia]] or mixed [[dyslipidemia]]. Lipid-altering agents should be used in addition to a diet restricted in saturated fat and [[cholesterol]] when response to diet and nonpharmacological interventions alone has been inadequate.
| |
| | |
| Pediatric Patients 10 to 17 years of age with Heterozygous Familial [[Hypercholesterolemia]] (HeFH)
| |
| | |
| Adjunct to diet to reduce Total‑C, LDL‑C and ApoB levels in adolescent boys and girls, who are at least one year post-menarche, 10‑17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL‑C > 190 mg/dL or > 160 mg/dL and there is a positive family history of premature [[cardiovascular disease]] ([[CVD]]) or two or more other [[CVD]] risk factors.
| |
| | |
| ===Hypertriglyceridemia===
| |
| | |
| CRESTOR is indicated as adjunctive therapy to diet for the treatment of adult patients with [[hypertriglyceridemia]].
| |
| | |
| ===Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia)===
| |
| | |
| CRESTOR is indicated as an adjunct to diet for the treatment of patients with primary [[dysbetalipoproteinemia]] (Type III [[Hyperlipoproteinemia]]).
| |
| | |
| ===Homozygous Familial Hypercholesterolemia===
| |
| | |
| CRESTOR is indicated as adjunctive therapy to other lipid-lowering treatments (e.g., LDL apheresis) or alone if such treatments are unavailable to reduce LDL‑C, Total‑C, and ApoB in adult patients with homozygous familial [[hypercholesterolemia]].
| |
| | |
| ===Slowing of the Progression of Atherosclerosis===
| |
| | |
| CRESTOR is indicated as adjunctive therapy to diet to slow the progression of[[ atherosclerosis]] in adult patients as part of a treatment strategy to lower Total‑C and LDL‑C to target levels.
| |
| | |
| ===Primary Prevention of Cardiovascular Disease===
| |
| | |
| In individuals without clinically evident coronary heart disease but with an increased risk of cardiovascular disease based on age ≥ 50 years old in men and ≥ 60 years old in women, hsCRP ≥ 2 mg/L, and the presence of at least one additional cardiovascular disease risk factor such as [[hypertension]], low HDL‑C, smoking, or a family history of premature coronary heart disease, CRESTOR is indicated to:
| |
| | |
| *reduce the risk of [[stroke]]
| |
| | |
| *reduce the risk of [[myocardial infarction]]
| |
| | |
| *reduce the risk of arterial revascularization procedures
| |
| | |
| === Limitations of Use===
| |
| | |
| CRESTOR has not been studied in Fredrickson Type I and V [[dyslipidemia]]s.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = CRESTOR (ROSUVASTATIN CALCIUM) TABLET, FILM COATED [ASTRAZENECA PHARMACEUTICALS LP] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bb0f3b5e-4bc6-41c9-66b9-6257e2513512 | publisher = | date = | accessdate = 17 February 2014 }}</ref>
| |
| | |
| ==References==
| |
| {{Reflist|2}}
| |
| | |
| {{Statins}}
| |
| {{AstraZeneca}}
| |
| | |
| [[Category:Statins]]
| |
| [[Category:AstraZeneca]]
| |
| [[Category:Diols]]
| |
| [[Category:Carboxylic acids]]
| |
| [[Category:Sulfonamides]]
| |
| [[Category:Pyrimidines]]
| |
| [[Category:Organofluorides]] | |